Valink Therapeutics logo

Valink Therapeutics

Making better ADCs

31 employees · est. 2020 · Cambridge, United States

VS
OncoResponse logo

OncoResponse

Interrogating for Cures

10 employees · est. 2016 · Houston, United States

OncoResponse is the older company (2020 vs 2016); Valink Therapeutics is the larger of the two.

Side-by-Side Comparison

Valink Therapeutics OncoResponse
Founded
2020 2016 older
Headquarters
Cambridge, United States Houston, United States
Employees
31 larger 10
Industry
Biotechnology, Health Care, Health and Wellness Biopharma, Biotechnology, Health Care
Funding Stage
Seed Unknown
Total Funding
Not tracked yet $117.10M
Funding Rounds
2 6
Services
Drug Discovery and Development, Therapeutic Design and Optimization, Biologics Research, Pipeline Development Development of novel cancer immunotherapies, Discovery of human antibodies, Partnering with collaborators in immuno-oncology, Preclinical studies
Target Customers
Pharmaceutical Companies, Biotech Researchers, Medical Professionals, Cancer Treatment Facilities, Healthcare Institutions Biopharmaceutical companies, Oncology researchers, Cancer patients, Clinical study collaborators
Taxonomy
Antibody-Drug Conjugates, BsADCs, Platform Therapeutics, Oncology, Solid Tumors, Multivalent Antibodies, Bispecific Antibodies, Novel Target Combinations, Protein Technology Platform, Biologics Discovery, Venture Capital-backed, Y Combinator-incubated, University Spin-out Immuno-oncology, Biotech, Cancer Immunotherapy, Antibody Platform, B-cell Discovery, Tumor Microenvironment, Monoclonal Antibodies, Immune Activation, TME Immunosuppression, Elite Cancer Responders, Novel Therapeutics, Myeloid Biology, Clinical Trials, Human Antibodies
Website
valinktx.com oncoresponse.com
Valink Therapeutics logo

About Valink Therapeutics

Valink Therapeutics, with its slogan "Making better ADCs," is pioneering the development of novel multivalent bispecific antibody-drug conjugates (bsADCs) designed to revolutionize the treatment of solid tumors and other critical health conditions. The company's innovative approach focuses on non-ob...

OncoResponse logo

About OncoResponse

OncoResponse, founded in 2016, is an innovative player in the immuno-oncology biotech sector. This biopharma company is particularly notable for its strategic collaboration with the MD Anderson Cancer Center, which amplifies its capabilities in treating cancer. Utilizing a proprietary B-cell discov...

We will tell you when either one moves

BounceWatch watches Valink Therapeutics and OncoResponse for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Valink Therapeutics and OncoResponse — by email.

Frequently Asked Questions

Valink Therapeutics — Making better ADCs. OncoResponse — Interrogating for Cures. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Valink Therapeutics has raised undisclosed funding while OncoResponse has raised $117.10M.
Valink Therapeutics and OncoResponse operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Valink Therapeutics with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Valink Therapeutics on 22 Mar 2026, and OncoResponse on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy